Rare variants in CYP2C9 and CYP3A5 detected in patients with familial hypercholesterolemia with statin-related adverse events (2018)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidade: FCF
- DOI: 10.1515/dmpt-2018-0024
- Subjects: ESTATINAS; HIPERCOLESTEROLEMIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Drug Metabolism and Personalized Therapy
- ISSN: 2363-8915
- Volume/Número/Paginação/Ano: v. 33, n. 3, p. eA52-eA53, 2018
- Conference titles: Santorini Conference Systems Medicine and Personalised Health & Therapy
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
HERNANDEZ, Carolina Dagli et al. Rare variants in CYP2C9 and CYP3A5 detected in patients with familial hypercholesterolemia with statin-related adverse events. Drug Metabolism and Personalized Therapy. Berlin: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1515/dmpt-2018-0024. Acesso em: 23 abr. 2024. , 2018 -
APA
Hernandez, C. D., Borges, J. B., Los, B., Faludi, A. A., Gonçalves, R. M., Hirata, M. H., & Hirata, R. D. C. (2018). Rare variants in CYP2C9 and CYP3A5 detected in patients with familial hypercholesterolemia with statin-related adverse events. Drug Metabolism and Personalized Therapy. Berlin: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1515/dmpt-2018-0024 -
NLM
Hernandez CD, Borges JB, Los B, Faludi AA, Gonçalves RM, Hirata MH, Hirata RDC. Rare variants in CYP2C9 and CYP3A5 detected in patients with familial hypercholesterolemia with statin-related adverse events [Internet]. Drug Metabolism and Personalized Therapy. 2018 ; 33( 3): eA52-eA53.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1515/dmpt-2018-0024 -
Vancouver
Hernandez CD, Borges JB, Los B, Faludi AA, Gonçalves RM, Hirata MH, Hirata RDC. Rare variants in CYP2C9 and CYP3A5 detected in patients with familial hypercholesterolemia with statin-related adverse events [Internet]. Drug Metabolism and Personalized Therapy. 2018 ; 33( 3): eA52-eA53.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1515/dmpt-2018-0024 - Could SNPs predict Cisplatin toxicity?
- Validation of TREML4 mRNA expression and polymorphisms in blood leukocytes as potential biomarker of atherosclerosis
- Bases farmacogenômicas da resistência medicamentosa
- Inclusion body formation in escherichia coli: a procedure for optimizing production of soluble protein in application to human interferon alpha receptor
- Expression of three polypeptide kfragments of human interferon alpha receptor cloning flexibility and optimization of expression efficienty
- Reconhecimento do receptor recombinante de ifn 'ALFA' / 'BETA' humano por anticorpos policlonais de coelho
- Human interferon alpha receptor: identification of the regeion involved in binding to interferon alpha b
- Cloning and expression of treponema pallidium 47 kda antigen in e. Coli dh5 'ALPHA'
- Estratégia de extração de DNA de manchas sanguíneas para testes forensicos por PCR
- Cloning of a fragment of the 5 noncoding region of HCV genome for using as an internal control in PCR
Informações sobre o DOI: 10.1515/dmpt-2018-0024 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
